Global Hemophilia Gene Therapy Market Size, Status and Forecast 2020-2026

Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
About 80% of them have hemophilia A, which affects the clotting factor VIII. The second most common form, hemophilia B, is due to a deficiency of the clotting factor IX. Several biotechs are racing to launch the first gene therapy for hemophilia. Currently, uniQure in the Netherlands and Spark Therapeutics in the US have the most advanced programs. Spark scored a victory in December when it presented Phase I/II for its candidate SPK-9001. The gene therapy was able to reduce annual bleeding episodes by 97%, as compared to its competitor uniQure’s candidate, AMT-060. However, uniQure has fought back. The company added a modification in its gene therapy that is known to increase clotting activity by 8- to 9- fold. This improved version has already been cleared to start a Phase III clinical trial in both Europe and the US.
Market Analysis and Insights: Global Hemophilia Gene Therapy Market
In 2019, the global Hemophilia Gene Therapy market size was US$ xx million and it is expected to reach US$ xx million by the end of 2026, with a CAGR of xx% during 2021-2026.
Global Hemophilia Gene Therapy Scope and Market Size
Hemophilia Gene Therapy market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hemophilia Gene Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the Hemophilia Gene Therapy market is segmented into Hemophilia A, Hemophilia B, etc.
Segment by Application, the Hemophilia Gene Therapy market is segmented into Hemophilia A Gene Therapy, Hemophilia B Gene Therapy, etc.
Regional and Country-level Analysis
The Hemophilia Gene Therapy market is analysed and market size information is provided by regions (countries).
The key regions covered in the Hemophilia Gene Therapy market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.

Competitive Landscape

and Hemophilia Gene Therapy Market Share Analysis
Hemophilia Gene Therapy market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Hemophilia Gene Therapy business, the date to enter into the Hemophilia Gene Therapy market, Hemophilia Gene Therapy product introduction, recent developments, etc.
The major vendors include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure, Freeline Therapeutics, etc.

This report focuses on the global Hemophilia Gene Therapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Hemophilia Gene Therapy development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Spark Therapeutics
Ultragenyx
Shire PLC
Sangamo Therapeutics
Bioverativ
BioMarin
uniQure
Freeline Therapeutics

Market segment by Type, the product can be split into

Hemophilia A
Hemophilia B

Market segment by Application, split into

Hemophilia A Gene Therapy
Hemophilia B Gene Therapy

Market segment by Regions/Countries, this report covers

North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:

To analyze global Hemophilia Gene Therapy status, future forecast, growth opportunity, key market and key players.
To present the Hemophilia Gene Therapy development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Hemophilia Gene Therapy are as follows:
History Year: 2015-2019

Base Year:

2019

Estimated Year:

2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Frequently Asked Questions